Immunovant, Inc. Units
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch IMVTU and buy or sell other stocks, ETFs, and their options commission-free!About IMVTU
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOEric Venker, MD, PharmD
CEOEric Venker, MD, PharmD
Employees362
Employees362
HeadquartersDurham, North Carolina
HeadquartersDurham, North Carolina
Founded2018
Founded2018
Employees362
Employees362
IMVTU Key Statistics
Market cap6.16B
Market cap6.16B
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume183.20
Average volume183.20
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$33.30
52 Week high$33.30
52 Week low$10.32
52 Week low$10.32
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.